| |||||||||
|
0%
agree
|
The Plavix situation |
|
0%
agree
|
Proportionally lower R&D spending than many competitors |
|
25%
agree
|
Few to no products in early development or testing |
![]()
|
|||||||||||||||||||||
| ||||||